Open AccessBrexucabtagene Autoleucel (Tecartus)
Author(s) -
Reimbursement Team
Publication year - 2021
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2021.135
Subject(s) - bruton's tyrosine kinase , ibrutinib , mantle cell lymphoma , medicine , refractory (planetary science) , lymphoma , tyrosine kinase inhibitor , oncology , tyrosine kinase , drug , cancer research , pharmacology , leukemia , cancer , biology , receptor , chronic lymphocytic leukemia , astrobiology
CADTH recommends that Tecartus should be reimbursed by public drug plans for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL) after 2 or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor if certain conditions are met.
Tecartus should only be reimbursed if prescribed as a one-time therapy by experienced specialists in centres delivering cellular therapies, and the cost of Tecartus is reduced.
Tecartus should only be covered to treat patients with R/R MCL who have received treatment with a BTK inhibitor (ibrutinib or acalabrutinib) and are in a clinically reasonable health status to tolerate the treatment.